Schering-Plough Licenses ViroPharma’s Pleconaril For Common Cold
Executive Summary
Schering-Plough will assume development responsibilities from ViroPharma for intranasal pleconaril, currently in Phase II
You may also be interested in...
Schering To Fund Picovir Studies Under Development Deal With ViroPharma
Schering-Plough will decide whether to fund additional development of ViroPharma's Picovir after assessing preclinical and Phase I data for an intranasal formulation of the common cold treatment in mid-2004
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials